{
  "id": 6053760,
  "title": "Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million",
  "url": "https://urgent.news/2026/09/06/arrowhead-pharmaceuticals-director-sells-11-600-shares-for-1-million-6053760",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-06T22:15:01.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/arrowhead-pharmaceuticals-director-sells-11-221501169.html"
  },
  "original_language": "en",
  "account": "Michael S. Perry, a Director at Arrowhead Pharmaceuticals, sold 11,600 of the company's common shares on August 18, 2026, according to an SEC Form 4 filing. The transaction value was estimated at $1 million based on the weighted average sale price of $87.30 per share, while the post-transaction value, using the closing price on August 18, 2026, was $87.90 per share. The director executed the sale in multiple transactions, with prices ranging from $87.20 to $87.44 per share. This move reduced Perry's direct ownership in the company by 9%, but he still maintains a stake, holding 0.0791% of the company's equity and retaining common shares tied to unvested restricted stock units. Arrowhead Pharmaceuticals, a Pasadena-based biotechnology firm with a market capitalization of $12.2 billion, is focused on developing RNA interference-based therapies for rare genetic diseases and complex liver conditions. The company reported $669.5 million in trailing twelve-month revenue, along with a net loss of $320 million. Despite the recent stock price surge of over 217.7% in the last year, outpacing the S&P 500's 18.8% growth, analysts remain cautious, with mixed price targets ranging from $100 to $126, representing potential gains of 15.8% to 46%.",
  "summary": null,
  "key_points": [
    "Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals on August 18, 2026.",
    "Sale value estimated at $1 million based on $87.30 per share weighted average price.",
    "Perry retains 0.0791% equity stake, holding vested restricted stock units."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million",
        "url": "https://urgent.news/2026/09/06/arrowhead-pharmaceuticals-director-sells-11-600-shares-for-1-million",
        "published": "2026-09-06T21:55:01.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million",
        "url": "https://urgent.news/2026/09/06/arrowhead-pharmaceuticals-director-sells-11-600-shares-for-1-million-6053095",
        "published": "2026-09-06T22:15:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}